The cannabinoid receptor 1 (CB 1 ) is the principal target of the psychoactive constituent of
marijuana, the partial agonist Δ 9 -tetrahydrocannabinol (Δ 9 -THC) 1 . Here we report two …

Abstract Structure-based virtual ligand screening is emerging as a key paradigm for early drug
discovery owing to the availability of high-resolution target structures 1 , 2 , 3 – 4 and ultra-…

Human endocannabinoid systems modulate multiple physiological processes mainly through
the activation of cannabinoid receptors CB1 and CB2. Their high sequence similarity, low …

Endocannabinoids (eCBs) are endogenous ligands of the cannabinoid receptor 1 (CB1), a
G protein-coupled receptor that regulates a number of therapeutically relevant physiological …

The CB1 receptor is expressed in the central nervous system and numerous other tissues
including heart, lung and uterus and has been recognized as an important therapeutic target …

Δ 9-Tetrahydrocannabinol (THC) has been characterized as a partial agonist at cannabinoid
CB1 receptors in vitro; however, it often produces the same maximum effects in vivo as …

The enzyme fatty acid amide hydrolase (FAAH) catalyzes the in vivo degradation of the
endocannabinoid anandamide, thus controlling its action at receptors. A novel FAAH inhibitor, …

In pursuit of a more detailed understanding of the structural requirements for the key side
chain cannabinoid pharmacophore, we have extended our SAR to cover a variety of …

Introduction: G-protein-coupled receptors (GPCRs) mediate the effects of approximately 33%
of all marketed drugs. The development of tools to study GPCR pharmacology is urgently …

AM1710 (3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c) chromen-6-one), a
cannabilactone cannabinoid receptor 2 (CB2) agonist, suppresses chemotherapy-induced …